C71T
CANCELLED SECTION 71
03/06/2026
Back to search
Official data from USPTO
GMP ORPHAN DRUGS FOR ORPHAN DISEASES
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
42
Latest update
03/31/2026
Trademark type
Combined
Nice classes
5, 10, 42, 44
Filing date
05/14/2013
Registration date
06/03/2014
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
03/06/2026
Last transaction
03/31/2026
Responsible office
United States Patent and Trademark Office
Status code
709
Official register
Principal Register
Drawing code
3
Owner type
99
Owner location
FR
Examiner
SPRUILL, DARRYL M
Law office
M30
Mark description
The mark consists of the literal stylized wording "gmp orphan drugs for orphan diseases". The wording "gmp" and "drugs for orphan diseases" appear in the color white, and the wording "orphan" is in black. The wording "gmp" is displayed with the letter "o" of the wording "orphan" above the wording "drugs for orphan diseases" all in a blue box, and the letters "rphan" appear outside of the box.
Holders and representatives
Holders
ORPHALAN
GMP-ORPHAN
Representatives
Heather Smith-Carra Banner & Witcoff, Ltd.
Technical classification
Nice Classes
Class 5Class 10Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical and veterinary products for the treatment of orphan diseases; medication for the treatment of orphan diseases; pharmaceutical and veterinary products for pediatric use for the treatment of orphan diseases; medication for pediatric use for the treatment of orphan diseases; chemical preparations for medical or pharmaceutical use in the treatment of childhood diseases; pharmaceutical and veterinary products and medicines for the treatment of orphan diseasesparticularly spinal muscular atrophysickle-cell anemiaprogressive nuclear palsyamyotrophic lateral sclerosis (ALS)cystic fibrosisDuchenne muscular dystrophymacrophagic myofasciitislysosomal storage diseaseleukodystrophy; pharmaceutical and veterinary products and medicines for the treatment of hyperammonemia of all kinds
Class 10
Medicalsurgical and veterinary apparatus and instrumentsfor diagnosis and treatmentparticularly in connection with orphan diseases; medical devices containing chemical products for diagnostic use of orphan diseases; medical diagnosis apparatus and instruments to diagnose orphan diseases; automatic testing apparatus to diagnose orphan diseasesfor medical usealso in the form of kits; medical apparatus and instruments in the form of kits for detecting the presence of analytes in biological fluidsother fluids and other structures; immunochemical testing apparatus for medical use; blood testing apparatus; radiological apparatus for medical use; resuscitation apparatus; medical imaging apparatus incorporating medical imaging software; needles for medical use; gloves for medical use; syringes for medical use; inhalers for medical purposes; injectors for medical use; X-ray photographs for medical use; radiology screens for medical use; receptacles for applying medicines; containers especially made for medical waste; probes for medical use; stethoscopes; heart pacemakers; thermometers for medical use; cases fitted for medical instruments for use by surgeons or doctors
Class 42
Evaluationsassessments and research in the fields of science; research and development services in the field of medicine; research and development of new products for othersmedical diagnosis apparatus; research and development in the field of biotechnology; scientific research for medical purposes; scientific laboratory services in the medical field; all the aforesaid services in connection with the treatment of childhood and orphan diseasesparticularly spinal muscular atrophysickle-cell anemiaprogressive nuclear palsyamyotrophic lateral sclerosis (ALS)cystic fibrosisDuchenne muscular dystrophymacrophagic myofasciitislysosomal storage diseaseleukodystrophy
Class 44
Medical services; medical and sanitary caretelemedecine services including remote diagnosis or medical follow-up; medical testing for the diagnosis and treatment of persons; providing medical advice on health matters in the field of medication administration; providing medical advisory services relating to medical apparatus and instruments; medical diagnosis services of orphan diseases; providing medical informationall the aforesaid services in connection with the treatment of childhood and orphan diseasesparticularly spinal muscular atrophysickle-cell anemiaprogressive nuclear palsyamyotrophic lateral sclerosis (ALS)cystic fibrosisDuchenne muscular dystrophymacrophagic myofasciitislysosomal storage diseaseleukodystrophy
Publications
History of USPTO decisions and trademark events.
42 publications found
RNWL
INTERNATIONAL REGISTRATION RENEWED
06/09/2023
REM4
COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED
06/03/2023
INNP
PARTIAL INVALIDATION PROCESSED BY THE IB
12/05/2021
INPS
PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
10/27/2021
INPC
INVALIDATION PROCESSED
10/27/2021
INPR
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
10/06/2021
NA71
NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
02/06/2021
71.P
REGISTERED - PARTIAL SEC 71 ACCEPTED
02/06/2021
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
02/01/2021
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
01/29/2021
ES71
TEAS SECTION 71 RECEIVED
12/03/2020
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
06/03/2019
NREP
NEW REPRESENTATIVE AT IB RECEIVED
02/07/2019
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
02/08/2018
NREP
NEW REPRESENTATIVE AT IB RECEIVED
03/03/2016
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
11/21/2014
FICS
FINAL DISPOSITION NOTICE SENT TO IB
10/21/2014
FIMP
FINAL DISPOSITION PROCESSED
10/21/2014
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
09/03/2014
R.PR
REGISTERED-PRINCIPAL REGISTER
06/03/2014
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
03/18/2014
PUBO
PUBLISHED FOR OPPOSITION
03/18/2014
GPNX
NOTIFICATION PROCESSED BY IB
03/14/2014
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
02/26/2014
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
02/26/2014
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
02/26/2014
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
02/07/2014
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
02/05/2014
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
02/05/2014
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
02/05/2014
ALIE
ASSIGNED TO LIE
01/30/2014
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
01/22/2014
RFNT
REFUSAL PROCESSED BY IB
09/30/2013
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
09/11/2013
RFRR
REFUSAL PROCESSED BY MPU
09/11/2013
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
09/11/2013
CNRT
NON-FINAL ACTION WRITTEN
09/10/2013
DOCK
ASSIGNED TO EXAMINER
09/03/2013
MAFR
APPLICATION FILING RECEIPT MAILED
08/16/2013
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
08/12/2013
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
08/08/2013
Continuous trademark protection
Get notified about every new filing that threatens GMP ORPHAN DRUGS FOR ORPHAN DISEASES or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.